The stock of FibroGen Inc (NASDAQ:FGEN) is a huge mover today! The stock increased 5.02% or $1.1 on November 23, hitting $23. About 390,143 shares traded hands. FibroGen Inc (NASDAQ:FGEN) has risen 11.38% since April 22, 2016 and is uptrending. It has outperformed by 5.97% the S&P500.
The move comes after 5 months positive chart setup for the $1.38 billion company. It was reported on Nov, 24 by Barchart.com. We have $24.15 PT which if reached, will make NASDAQ:FGEN worth $69.00 million more.
Analysts await FibroGen Inc (NASDAQ:FGEN) to report earnings on March, 6. They expect $-0.65 earnings per share, up 23.53% or $0.20 from last year’s $-0.85 per share. After $-0.38 actual earnings per share reported by FibroGen Inc for the previous quarter, Wall Street now forecasts 71.05% negative EPS growth.
FibroGen Inc (NASDAQ:FGEN) Ratings Coverage
Out of 3 analysts covering FibroGen Inc (NASDAQ:FGEN), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. FibroGen Inc has been the topic of 6 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by Lake Street on Wednesday, September 23. The firm earned “Buy” rating on Friday, December 4 by Citigroup. The firm earned “Outperform” rating on Thursday, February 11 by Credit Suisse. Credit Suisse initiated the shares of FGEN in a report on Thursday, January 21 with “Neutral” rating. Citigroup initiated it with “Buy” rating and $37 target price in Wednesday, July 29 report.
According to Zacks Investment Research, “FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.”
FGEN Company Profile
FibroGen, Inc., incorporated on September 29, 1993, is a research biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Firm focuses in the areas of fibrosis and hypoxia-inducible factor (HIF) biology and generates multiple programs targeting various therapeutic areas. The Company’s lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.